Study on a Prosthetic Foot With Adjustable Heel Height (ADJUST)

November 20, 2025 updated by: Otto Bock France SNC

Impact of a Prosthetic Foot With Adjustable Heel Height on Physical Appearance and Participation: a Randomized Crossover Trial.

Most prosthetic feet have a fixed heel height, which requires users to always wear shoes with the same heel height. A fixed heel height is a significant constraint, whereas the ability to choose one's clothing freely is an important aspect of coping with a physical disability.

The Taleo Adjust is a prosthetic foot with a hydraulic ankle that allows the user to adjust the heel height from 0 to 7 cm, depending on the type of shoe worn.

This study aims to evaluate the impact of an adjustable-heel-height foot on physical appearance and participation.

Study Overview

Detailed Description

The amputation or absence of a lower limb affects both mobility and appearance, which can lead to restrictions in social, family, and professional participation. The choice of prosthetic components aims to compensate as effectively as possible for the functional and physical disability, in line with the patient's expectations and life plan.

The prosthetic foot is a key component of the prosthesis. Most feet have a fixed heel height-most often around 10 to 15 mm-which requires users to always wear shoes with the same heel height, since prosthetic alignment, essential for harmonious and safe walking, is set accordingly.

A fixed heel height is a significant constraint for many users who wish to wear different types of shoes for aesthetic reasons (e.g., city shoes or pumps for work or going out; flip-flops or flat ballet flats in summer), for safety reasons (e.g., boots for motorcycling or gardening), or to be able to walk barefoot (e.g., at home). The ability to choose one's clothing freely is an important aspect of coping with a physical disability.

The Taleo Adjust is an energy-storing and energy-returning prosthetic foot with a hydraulic ankle that allows the user to adjust the heel height from 0 to 7 cm, depending on the type of shoe worn. Thanks to this articulation, prosthetic alignment is preserved and walking quality is not compromised.

This study aims to evaluate the impact of an adjustable-heel-height foot on physical appearance and participation.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Concarneau, France
        • Recruiting
        • Ch Cornouaille
      • Nancy, France
        • Recruiting
        • IRR Louis Pierquin
      • Saint-Herblain, France
        • Recruiting
        • CRRF La Tourmaline
      • Valenton, France
        • Recruiting
        • Institut Merle d'Aubigné
      • Échirolles, France
        • Recruiting
        • CHU Grenoble

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria :

  • Adult patient with a major lower limb amputation whose life project includes:
  • movement in buildings other than the home (ICF d4601),
  • movement outside the home and other buildings (ICF d4602),
  • and other specified activities related to movement in other various places (ICF d4608).
  • Patient who has been using an Enregy storage and Return (ESR) foot for at least 3 months
  • Patient who wishes to walk with shoes with different heel heights, and/or barefoot

Exclusion Criteria:

  • Patient with a high impact level (e.g.: sport)
  • Patient with hip disarticulation or equivalent
  • Patient with an unstabilised residual limb and/or an unsuitable socket
  • Patient who cannot be fitted with a Taleo Adjust foot due to the technical characteristics of the product (user weight greater than 115kg; required foot size <22 or >28; mounting height less than 118 mm)
  • Patient whose usual foot has a heel height adjustment system
  • Patient unavailable for the duration of the study and/or unable to understand the instructions and/or answer questionnaires in French
  • Patient already participating in another study
  • Patient in an emergency situation or pregnant woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Taleo Adjust foot then usual foot
The participant is first fitted with the Taleo Adjust foot for 30 days, then is fitted with their usual foot for 30 days.
The usual foot of the participant is an Energy Storage and Return (ESR) prosthetic foot (no heel height adjustement)
The Taleo Adjust foot is an energy-storage-and-return (ESR) prosthetic foot with a hydraulic ankle joint that allows an adjustable heel height from 0 to 7 cm.
Other: Usual foot then taleo Adjust foot
The participant is first fitted with their usual foot for 30 days, then fitted with the Taleo Adjust foot for 30 days
The usual foot of the participant is an Energy Storage and Return (ESR) prosthetic foot (no heel height adjustement)
The Taleo Adjust foot is an energy-storage-and-return (ESR) prosthetic foot with a hydraulic ankle joint that allows an adjustable heel height from 0 to 7 cm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prosthetic Evaluation Questionnaire - Appearance scale (PEQ-AP)
Time Frame: 30 days
A 5-item self-reported measure of the appearance domain. The participant rates each item by marking a 100-mm line. Scores range from 0 to 100, with higher scores indicating a more positive perception.
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Specific functional Scale (PSFS)
Time Frame: 30 days
A self-reported measure of participation based on 3 to 5 self-selected activities that the participant cannot perform or can perform only with difficulty. Participants will be asked to rate their ability to perform each activity on a numerical scale from 0 (unable to perform the activity) to 10 (able to fully perform the activity).
30 days
Psychosocial Impact of Assistive Device Scale (PIADS)
Time Frame: 30 days
A 26-item questionnaire that assesses the effects of an assistive device on functional independence, well-being, and quality of life from the perspective of the person's disability. Each item is rated on a 7-point Likert scale ranging from -3 (maximum negative impact) to +3 (maximum positive impact).
30 days
Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)
Time Frame: 30 days
A 12-item self-reported measure of the participant's satisfaction with the device's technology and the services associated with it. An average satisfaction rating can be calculated on a scale from 1 to 5, with 1 = "Not at all satisfied" and 5 = "Very satisfied". A higher score indicates greater satisfaction. It also allows the participant to express the three criteria that are most important to them.
30 days
Visual Analog Scale (VAS) for the adequacy to life's project
Time Frame: 30 days
An 11-level numerical scale ranging from 0 (total dissatisfaction) to 10 (total satisfaction), measuring how well the device aligns with the participant's life project
30 days
EuroQuol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Time Frame: 30 days

A self-reported measure of health status composed of five dimensions: mobility, self-care, ability to perform usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-point scale. A utility index, which is a single value derived from a patient's responses to these dimensions, can be calculated using a population-specific value set, typically ranging from 0 (death) to 1 (perfect health).

Health status is also expressed using the EQ-VAS (Visual Analog Scale). The EQ-VAS records the patient's self-assessment of health on a vertical visual analog scale, ranging from 0 "The worst health you could imagine" to 100 "The best health you could imagine."

30 days
Prosthetic Limb Users Survey of Mobility (PLUS-M)
Time Frame: 30 days
A 12-items self-reported measure of mobility as the ability to move intentionally and independantly from one place to another. Questions cover movements that range from basic ambulation to complex activities . Response options going from 1 (unable to do) to 5 (without any difficulty), reflecting the degree of difficulty with which respondents report they can perform these activities. The PLUS-M™ 12-item short form provides a T-score ranging from 21.8 to 71.4, with higher scores indicating better mobility.
30 days
Socket Comfort Scale (SCS)
Time Frame: 30 days
A 11-levels numerical scale going from 0 (the most uncomfortable socket) to 10 (the most comfortable socket), measuring the perceived comfort in the socket.
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Brice LAVRARD, Dr., Institut Merle d'Aubigné - VALENTON
  • Study Chair: Isabelle LOIRET, IRR Louis Pierquin - NANCY

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 8, 2025

Primary Completion (Estimated)

June 6, 2026

Study Completion (Estimated)

June 6, 2026

Study Registration Dates

First Submitted

September 23, 2025

First Submitted That Met QC Criteria

October 2, 2025

First Posted (Estimated)

October 9, 2025

Study Record Updates

Last Update Posted (Actual)

November 25, 2025

Last Update Submitted That Met QC Criteria

November 20, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • BP-11-PT009

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lower Limb Amputation Below Knee

Clinical Trials on The usual participant's foot

Subscribe